Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TNK2 antisense RNA 1 (TNK2-AS1) is a long non-coding RNA transcribed from the DNA strand opposite to the TNK2 gene. It does not encode a protein but can regulate the expression of the TNK2 gene or coordinate with other regulatory processes. Antisense transcripts are recognized for their roles in post-transcriptional regulation via formation of RNA:RNA duplexes, masking, modulation of sense transcript stability, and impacting chromatin structure at associated gene loci. Although some antisense transcripts have been implicated in cancer and other diseases through epigenetic regulation of gene expression, TNK2-AS1 itself does not appear to be an established therapeutic target or drug receptor, and no current drugs or biomarkers are associated with it. There is also no evidence of direct safety concerns or therapeutic challenges for TNK2-AS1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TNK2 antisense RNA 1 (TNK2-AS1).